Want to see BRIA full AI Analyst Report?
BrilliA Inc. Class A (BRIA) Stock Forecast & Price Target
BRIA Analyst Ratings
There are no analyst ratings in the last 3 months.
BRIA Stock 12 Month Forecast
There are no analyst price targets in the last 3 months.
Detailed List of Analyst Forecasts
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Aaron Grey | Alliance Global Partners | $2.75 | buy | 99.28%Upside | Reiterated | 06/05/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Aaron GreyAlliance Global Partners | BuyReiterated$2.75 | 06/05/26 | 99.28%Upside |
Best Analysts Covering BrilliA Inc. Class A
Copying Aaron Grey's trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -19.83% per trade.
Copying Aaron Grey's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -25.50% per trade.
Copying Aaron Grey's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -25.13% per trade.
BRIA Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 0 | 0 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 1 | 1 | 0 | 0 | 0 |
In the current month, BRIA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. BRIA average Analyst price target in the past 3 months is ―.
BRIA Financial Forecast
BRIA Earnings Forecast
Next quarter’s earnings estimate for BRIA is $0.04 with a range of $0.04 to $0.04. The previous quarter’s EPS was $0.00. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
BRIA Sales Forecast
Next quarter’s sales forecast for BRIA is $29.75M with a range of $29.75M to $29.75M. The previous quarter’s sales results were ―. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
